11.55
price up icon1.49%   0.17
after-market After Hours: 11.55
loading
Roivant Sciences Ltd stock is traded at $11.55, with a volume of 4.36M. It is up +1.49% in the last 24 hours and up +1.32% over the past month. Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
See More
Previous Close:
$11.38
Open:
$11.58
24h Volume:
4.36M
Relative Volume:
0.71
Market Cap:
$7.85B
Revenue:
$125.68M
Net Income/Loss:
$4.81B
P/E Ratio:
2.0442
EPS:
5.65
Net Cash Flow:
$-781.21M
1W Performance:
+0.96%
1M Performance:
+1.32%
6M Performance:
+3.40%
1Y Performance:
+7.54%
1-Day Range:
Value
$11.35
$11.64
1-Week Range:
Value
$11.31
$11.64
52-Week Range:
Value
$8.73
$13.05

Roivant Sciences Ltd Stock (ROIV) Company Profile

Name
Name
Roivant Sciences Ltd
Name
Phone
441-295-5950
Name
Address
7TH FLOOR, 50 BROADWAY, LONDON
Name
Employee
750
Name
Twitter
Name
Next Earnings Date
2025-02-10
Name
Latest SEC Filings
Name
ROIV's Discussions on Twitter

Compare ROIV with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
ROIV
Roivant Sciences Ltd
11.55 7.74B 125.68M 4.81B -781.21M 5.65
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
469.65 121.28B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
563.10 60.96B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.81 42.77B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.99 36.21B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
291.47 32.08B 3.81B -644.79M -669.77M -6.24

Roivant Sciences Ltd Stock (ROIV) Upgrades & Downgrades

Date Action Analyst Rating Change
Jul-10-25 Resumed Goldman Buy
Feb-15-24 Initiated Wolfe Research Outperform
Jan-05-24 Initiated Piper Sandler Overweight
Dec-12-23 Initiated Deutsche Bank Buy
Oct-17-23 Initiated Guggenheim Buy
Jun-08-23 Initiated BofA Securities Neutral
Oct-27-22 Initiated JP Morgan Overweight
May-23-22 Initiated SVB Leerink Outperform
Apr-29-22 Initiated Cantor Fitzgerald Overweight
Dec-15-21 Initiated Goldman Buy
Nov-08-21 Initiated H.C. Wainwright Buy
Oct-28-21 Initiated Citigroup Buy
Oct-26-21 Initiated Cowen Outperform
Oct-26-21 Initiated Jefferies Buy
Oct-26-21 Initiated Truist Buy
View All

Roivant Sciences Ltd Stock (ROIV) Latest News

pulisher
05:34 AM

What is the dividend policy of Roivant Sciences Ltd. stockCapitalize on trading strategies that deliver - jammulinksnews.com

05:34 AM
pulisher
03:43 AM

How volatile is Roivant Sciences Ltd. stock compared to the marketBuild a portfolio that outperforms the market - jammulinksnews.com

03:43 AM
pulisher
06:41 AM

Does Roivant Sciences Ltd. stock perform well during market downturnsCapitalize on emerging trends for profits - jammulinksnews.com

06:41 AM
pulisher
Jul 25, 2025

Is Roivant Sciences Ltd. a good long term investmentUnbelievable profit margins - Autocar Professional

Jul 25, 2025
pulisher
Jul 25, 2025

Roivant Sciences (ROIV) Anticipated to Benefit from Brepocitinib Developments | ROIV Stock News - GuruFocus

Jul 25, 2025
pulisher
Jul 25, 2025

Goldman Sachs Resumes Roivant Sciences (ROIV) Coverage with ‘Buy’ Rating - MSN

Jul 25, 2025
pulisher
Jul 25, 2025

Vivek Ramaswamy to welcome third child soon: Meet his wife and his two elder sons - Times of India

Jul 25, 2025
pulisher
Jul 24, 2025

Roivant Sciences Ltd. Stock Analysis and ForecastFree Stock Market Beginners Guide - Autocar Professional

Jul 24, 2025
pulisher
Jul 23, 2025

Roivant Sciences’ president Venker sells $1.15 million in shares By Investing.com - Investing.com South Africa

Jul 23, 2025
pulisher
Jul 23, 2025

Roivant Sciences’ president Venker sells $1.15 million in shares - Investing.com Australia

Jul 23, 2025
pulisher
Jul 23, 2025

Roivant Sciences President Eric Venker Sells 100k Shares at $11.52, Buys 100k at $3.85. - AInvest

Jul 23, 2025
pulisher
Jul 23, 2025

10 Best Biotech Stocks to Buy According to Billionaire Steve Cohen - Insider Monkey

Jul 23, 2025
pulisher
Jul 23, 2025

What drives Roivant Sciences Ltd. stock priceExceptional risk-adjusted gains - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 23, 2025

What analysts say about Roivant Sciences Ltd. stockTriple-digit profit margins - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 18, 2025

(ROIV) Investment Analysis and Advice - news.stocktradersdaily.com

Jul 18, 2025
pulisher
Jul 10, 2025

Goldman Sachs resumes Roivant Sciences stock coverage with Buy rating By Investing.com - Investing.com South Africa

Jul 10, 2025
pulisher
Jul 10, 2025

Goldman Sachs resumes Roivant Sciences stock coverage with Buy rating - Investing.com India

Jul 10, 2025
pulisher
Jul 07, 2025

How to Take Advantage of moves in (ROIV) - news.stocktradersdaily.com

Jul 07, 2025
pulisher
Jul 05, 2025

Roivant Sciences: Booming Pipeline Without Product Revenues Creates Valuation Riddle - Seeking Alpha

Jul 05, 2025
pulisher
Jun 26, 2025

'Just the beginning': Vivek Ramaswamy breaks record in raising fund for Guv election campaign, $8.5 milli - Times of India

Jun 26, 2025
pulisher
Jun 25, 2025

Hedge Fund and Insider Trading News: Ken Griffin, Warren Buffett, Michael Burry, AQR Capital Management, Tiger Global Management, Amplify Energy Corp (AMPY), Roivant Sciences ltd (ROIV), and More - Insider Monkey

Jun 25, 2025
pulisher
Jun 24, 2025

Roivant Sciences Subsidiary Pulmovant Publishes Positive Phase 1 Data for Inhaled PH Treatment Mosliciguat - Yahoo Finance

Jun 24, 2025
pulisher
Jun 23, 2025

Roivant Sciences (ROIV): Ramaswamy sells $13 million in shares - Investing.com

Jun 23, 2025
pulisher
Jun 18, 2025

HC Wainwright & Co. Reiterates Buy Rating for Roivant Sciences (ROIV) | ROIV Stock News - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Cantor Fitzgerald reiterates overweight rating on Roivant Sciences stock By Investing.com - Investing.com India

Jun 18, 2025
pulisher
Jun 18, 2025

H.C. Wainwright reiterates buy rating on Roivant Sciences stock By Investing.com - Investing.com India

Jun 18, 2025
pulisher
Jun 18, 2025

Guggenheim maintains buy rating on Roivant Sciences stock amid DM study - Investing.com India

Jun 18, 2025
pulisher
Jun 18, 2025

JPMorgan Maintains Positive Outlook on Roivant Sciences (ROIV) | ROIV Stock News - GuruFocus

Jun 18, 2025
pulisher
Jun 17, 2025

Roivant (ROIV) Hosts Investor Webinar on Brepocitinib's Role in Dermatomyositis | ROIV Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 16, 2025

Long Term Trading Analysis for (ROIV) - news.stocktradersdaily.com

Jun 16, 2025
pulisher
Jun 16, 2025

Roivant (ROIV) Publishes Promising Phase 1 Results for Inhaled M - GuruFocus

Jun 16, 2025
pulisher
Jun 10, 2025

Roivant Sciences at Goldman Sachs Conference: Strategic Execution Focus By Investing.com - Investing.com South Africa

Jun 10, 2025
pulisher
Jun 10, 2025

Roivant Sciences at Goldman Sachs Conference: Strategic Execution Focus - Investing.com Australia

Jun 10, 2025
pulisher
Jun 09, 2025

Roivant and Priovant to Host Investor Video Conference at 1:00 PM ET on Tuesday, June 17 on Brepocitinib and the Unmet Medical Need in Dermatomyositis - Yahoo Finance

Jun 09, 2025
pulisher
Jun 09, 2025

Rare Disease Breakthrough: Roivant Reveals Brepocitinib Data for Dermatomyositis Treatment - Stock Titan

Jun 09, 2025
pulisher
Jun 07, 2025

Major Shareholder Cashes Out Millions in Roivant Sciences Stock - TipRanks

Jun 07, 2025
pulisher
Jun 04, 2025

(ROIV) Trading Advice - news.stocktradersdaily.com

Jun 04, 2025
pulisher
May 31, 2025

Vivek Ramaswamy’s firm wants to buy biotech companies to bet on bitcoin - MSN

May 31, 2025
pulisher
May 31, 2025

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $324,000 Stock Holdings in Roivant Sciences Ltd. (NASDAQ:ROIV) - Defense World

May 31, 2025

Roivant Sciences Ltd Stock (ROIV) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$23.40
price down icon 0.97%
$36.67
price up icon 0.22%
$103.95
price up icon 0.42%
$28.67
price up icon 3.99%
$115.31
price up icon 0.65%
biotechnology ONC
$291.47
price down icon 1.68%
Cap:     |  Volume (24h):